Compugen, a clinical-stage cancer immunotherapy company, has announced the successful dosing of the first patient in a study that aims to evaluate the effectiveness of a triple immunotherapy combination for treating platinum-resistant ovarian cancer. The study builds on previous clinical benefits reported in heavily pretreated platinum-resistant ovarian cancer patients who were treated with dual or triple combinations of drugs. The initial findings are expected by the end of 2023.
The trial will assess COM701, Compugen's potential first-in-class anti-PVRIG antibody, with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in up to 40 patients with high-grade platinum-resistant epithelial ovarian cancer including fallopian tube cancer and primary peritoneal cancer who have received up to three lines of prior therapy for platinum-resistant ovarian cancer. The goal is to build on encouraging data previously reported by Compugen at the ESMO Immuno-Oncology Congress 2022, with the dual and triple blockade of PVRIG and PD-1 with or without TIGIT.
Compugen utilizes predictive computational discovery